COMMUNIQUÉS West-GlobeNewswire

Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
08/01/2018
BERKELEY, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX ) today announced that HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] is now available in the United States [...]
Tecan to present at J.P. Morgan Healthcare Conference
08/01/2018
Männedorf, Switzerland, January 8, 2018 - The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will present at J.P. Morgan Healthcare Conference on January 11, 2018. The investor presentation by David [...]
Wright Medical Group N.V. Announces Preliminary Fourth Quarter and Full-Year 2017 Net Sales
08/01/2018
Fourth Quarter 2017 Net Sales of Approximately $218 Million Full-Year 2017 Net Sales of Approximately $745 Million At High-End Of Company’s Previously Provided 2017 Guidance Range Company to Present Today at J.P. Morgan [...]
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi
08/01/2018
VIENNA, Austria and HAMBURG, Germany, Jan. 08, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, and Evotec AG (Frankfurt Stock Exchange:EVT) (TecDAX) (ISIN:DE0005664809) [...]
Saniona AB: Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome
08/01/2018
PRESS RELEASE January 8, 2018 Saniona, a leading biotech company in the field of ion channels, today announced top line results from its exploratory Phase 2a clinical trial for Tesomet in patients with Prader-Willi [...]
WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER
08/01/2018
WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER Marseille, France, January 8, 2018 Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today [...]
IMMUNOLOGISTE DE RENOMMÉE MONDIALE, LE PROFESSEUR ÉRIC VIVIER EST NOMMÉ DIRECTEUR SCIENTIFIQUE D'INNATE PHARMA
08/01/2018
IMMUNOLOGISTE DE RENOMMÉE MONDIALE, LE PROFESSEUR ÉRIC VIVIER EST NOMMÉ DIRECTEUR SCIENTIFIQUE D'INNATE PHARMA Marseille, le 8 janvier 2018 Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) annonce [...]
Addex Therapeutics Equity Research Report Update Issued by valuationLAB
08/01/2018
Report estimates a current value of ADXN of CHF 12.5 per share Geneva, Switzerland, 8 January 2018 - Addex Therapeutics (SIX: ADXN) announced today that the independent life science equity research firm, valuationLAB AG [...]
Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
08/01/2018
Oslo, Norway, 8 January 2018: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that Michael Bogenstaetter [...]
ASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in China
08/01/2018
SINGAPORE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]
Mauricio Graber appointed new CEO of Chr. Hansen Holding A/S
08/01/2018
Company Announcement No. 1/2018 https://www.globenewswire.com/NewsRoom/AttachmentNg/d2eefaa4-165a-4d90-92bc-6ac719d2e9b0
Positive topline results with GLPG1972 in osteoarthritis patients
07/01/2018
Mechelen, Belgium; 7 January 2018, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports positive preliminary topline results with a Phase 1b study in osteoarthritis (OA) patients in the United States. [...]
Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
07/01/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance Restructuring enables streamlined development and optimization of [...]
Sanofi et Alnylam procèdent à une restructuration stratégique de leur alliance portant sur le développement d'agents ARNi dans le traitement de maladies rares
07/01/2018
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi et Alnylam procèdent à une restructuration stratégique de leur alliance portant sur le développement d'agents ARNi dans le traitement de maladies [...]
Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
07/01/2018
NOVATO, Cali., Jan. 07, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced [...]
Nexstim enrols last patient in supplementary Phase III E-FIT trial
06/01/2018
Company announcement, Helsinki, 6 January 2018 at 11.00 Nexstim enrols last patient in supplementary Phase III E-FIT trial Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company [...]
Alzheimer’s Foundation of America Offers Winter Weather Safety Tips For Families Whose Loved Ones Are Dealing With Alzheimer’s
06/01/2018
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- With extreme cold and winter storms bringing dangerously low temperatures, major snowfall and hazardous conditions to states across the US, the Alzheimer’s Foundation of [...]
Emerald Health Therapeutics Accelerates Expiry of 744,576 Remaining $2.60 Warrants
05/01/2018
VICTORIA, British Columbia, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“Emerald” or the “Company”) (TSXV:EMH) (OTCQX:EMHTF) has elected to exercise its right to accelerate the expiry of the $2. [...]
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
05/01/2018
GERMANTOWN, Md., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, chief science [...]

Pages